Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice

Hirofumi Kamata, Sadatomo Tasaka, Ken Ichiro Inoue, Keisuke Miyamoto, Yasushi Nakano, Hiromi Shinoda, Yoshifumi Kimizuka, Hiroshi Fujiwara, Makoto Ishii, Naoki Hasegawa, Rina Takamiya, Seitaro Fujishima, Hirohisa Takano, Akitoshi Ishizaka

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

With the recent increasing use of nanoparticles, there is concern that they may become an environmental risk factor as airborne particles. However, the impact of these particles on susceptible subjects with predisposing lung disease have not been sufficiently elucidated. In the present study, we investigated the effects of nanoparticles on pulmonary inflammatory and fibrotic changes induced by intratracheal bleomycin (BLM) challenge in mice. Mice were intratracheally administered either vehicle, 14-nm carbon black nanoparticles (CBNPs), BLM or BLM plus CBNP. First, we assessed lung collagen content, lung compliance and fibrotic changes in histopathology on day 21 after instillation. Then, to elucidate how CBNP contributes to the development of BLM-induced fibrosis, we collected bronchoalveolar lavage (BAL) fluid on days 2, 7, 14 and 21 and determined the total and differential cell counts and concentrations of two proinflammatory cytokines (keratinocyte chemoattractant [KC] and interleukin [IL]-6) and two fibrogenic mediators (CC chemokine ligand 2 [CCL2] and transforming growth factor-β 1 [TGF-β 1]). Expression of nitrotyrosine, an indicator of oxidant injury, was also evaluated on days 7 and 21. CBNP, when combined with BLM, significantly enhanced BLM-induced increase in lung collagen content, decrease in lung compliance, and fibrotic changes in histopathology. CBNP significantly augmented BLM-induced increase in the numbers of inflammatory cells in BAL fluid on days 2 and 7 and levels of KC and IL-6 on day 2. In addition, CBNP administered in combination with BLM significantly elevated the levels of CCL2 on days 2, 7 and 14, and TGF-β 1 on day 14 in BAL fluid as compared with BLM alone. Nitrotyrosine expression was also increased by BLM plus CBNP compared with BLM alone. In contrast, CBNP did not exert any significant effect on these parameters by itself. These results indicate that CBNP can exaggerate BLM-induced inflammatory and fibrotic changes in the lung, suggesting the potential impact of nanoparticles on lung inflammation and fibrosis.

Original languageEnglish
Pages (from-to)315-324
Number of pages10
JournalExperimental Biology and Medicine
Volume236
Issue number3
DOIs
Publication statusPublished - 2011 Mar

Fingerprint

Soot
Bleomycin
Nanoparticles
Lung
Bronchoalveolar Lavage Fluid
Lung Compliance
CC Chemokines
Chemotactic Factors
Transforming Growth Factors
Keratinocytes
Fluids
Interleukin-6
Fibrosis
Collagen
Cell Count
Ligands
Pulmonary diseases
Oxidants
Lung Diseases
Pneumonia

Keywords

  • Bleomycin
  • Lung inflammation
  • Nanoparticle
  • Oxidant injury
  • Pulmonary fibrosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice. / Kamata, Hirofumi; Tasaka, Sadatomo; Inoue, Ken Ichiro; Miyamoto, Keisuke; Nakano, Yasushi; Shinoda, Hiromi; Kimizuka, Yoshifumi; Fujiwara, Hiroshi; Ishii, Makoto; Hasegawa, Naoki; Takamiya, Rina; Fujishima, Seitaro; Takano, Hirohisa; Ishizaka, Akitoshi.

In: Experimental Biology and Medicine, Vol. 236, No. 3, 03.2011, p. 315-324.

Research output: Contribution to journalArticle

Kamata, H, Tasaka, S, Inoue, KI, Miyamoto, K, Nakano, Y, Shinoda, H, Kimizuka, Y, Fujiwara, H, Ishii, M, Hasegawa, N, Takamiya, R, Fujishima, S, Takano, H & Ishizaka, A 2011, 'Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice', Experimental Biology and Medicine, vol. 236, no. 3, pp. 315-324. https://doi.org/10.1258/ebm.2011.010180
Kamata, Hirofumi ; Tasaka, Sadatomo ; Inoue, Ken Ichiro ; Miyamoto, Keisuke ; Nakano, Yasushi ; Shinoda, Hiromi ; Kimizuka, Yoshifumi ; Fujiwara, Hiroshi ; Ishii, Makoto ; Hasegawa, Naoki ; Takamiya, Rina ; Fujishima, Seitaro ; Takano, Hirohisa ; Ishizaka, Akitoshi. / Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice. In: Experimental Biology and Medicine. 2011 ; Vol. 236, No. 3. pp. 315-324.
@article{9cdad3cfe753419c8fdafb337b8e5225,
title = "Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice",
abstract = "With the recent increasing use of nanoparticles, there is concern that they may become an environmental risk factor as airborne particles. However, the impact of these particles on susceptible subjects with predisposing lung disease have not been sufficiently elucidated. In the present study, we investigated the effects of nanoparticles on pulmonary inflammatory and fibrotic changes induced by intratracheal bleomycin (BLM) challenge in mice. Mice were intratracheally administered either vehicle, 14-nm carbon black nanoparticles (CBNPs), BLM or BLM plus CBNP. First, we assessed lung collagen content, lung compliance and fibrotic changes in histopathology on day 21 after instillation. Then, to elucidate how CBNP contributes to the development of BLM-induced fibrosis, we collected bronchoalveolar lavage (BAL) fluid on days 2, 7, 14 and 21 and determined the total and differential cell counts and concentrations of two proinflammatory cytokines (keratinocyte chemoattractant [KC] and interleukin [IL]-6) and two fibrogenic mediators (CC chemokine ligand 2 [CCL2] and transforming growth factor-β 1 [TGF-β 1]). Expression of nitrotyrosine, an indicator of oxidant injury, was also evaluated on days 7 and 21. CBNP, when combined with BLM, significantly enhanced BLM-induced increase in lung collagen content, decrease in lung compliance, and fibrotic changes in histopathology. CBNP significantly augmented BLM-induced increase in the numbers of inflammatory cells in BAL fluid on days 2 and 7 and levels of KC and IL-6 on day 2. In addition, CBNP administered in combination with BLM significantly elevated the levels of CCL2 on days 2, 7 and 14, and TGF-β 1 on day 14 in BAL fluid as compared with BLM alone. Nitrotyrosine expression was also increased by BLM plus CBNP compared with BLM alone. In contrast, CBNP did not exert any significant effect on these parameters by itself. These results indicate that CBNP can exaggerate BLM-induced inflammatory and fibrotic changes in the lung, suggesting the potential impact of nanoparticles on lung inflammation and fibrosis.",
keywords = "Bleomycin, Lung inflammation, Nanoparticle, Oxidant injury, Pulmonary fibrosis",
author = "Hirofumi Kamata and Sadatomo Tasaka and Inoue, {Ken Ichiro} and Keisuke Miyamoto and Yasushi Nakano and Hiromi Shinoda and Yoshifumi Kimizuka and Hiroshi Fujiwara and Makoto Ishii and Naoki Hasegawa and Rina Takamiya and Seitaro Fujishima and Hirohisa Takano and Akitoshi Ishizaka",
year = "2011",
month = "3",
doi = "10.1258/ebm.2011.010180",
language = "English",
volume = "236",
pages = "315--324",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "0037-9727",
publisher = "Society for Experimental Biology and Medicine",
number = "3",

}

TY - JOUR

T1 - Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice

AU - Kamata, Hirofumi

AU - Tasaka, Sadatomo

AU - Inoue, Ken Ichiro

AU - Miyamoto, Keisuke

AU - Nakano, Yasushi

AU - Shinoda, Hiromi

AU - Kimizuka, Yoshifumi

AU - Fujiwara, Hiroshi

AU - Ishii, Makoto

AU - Hasegawa, Naoki

AU - Takamiya, Rina

AU - Fujishima, Seitaro

AU - Takano, Hirohisa

AU - Ishizaka, Akitoshi

PY - 2011/3

Y1 - 2011/3

N2 - With the recent increasing use of nanoparticles, there is concern that they may become an environmental risk factor as airborne particles. However, the impact of these particles on susceptible subjects with predisposing lung disease have not been sufficiently elucidated. In the present study, we investigated the effects of nanoparticles on pulmonary inflammatory and fibrotic changes induced by intratracheal bleomycin (BLM) challenge in mice. Mice were intratracheally administered either vehicle, 14-nm carbon black nanoparticles (CBNPs), BLM or BLM plus CBNP. First, we assessed lung collagen content, lung compliance and fibrotic changes in histopathology on day 21 after instillation. Then, to elucidate how CBNP contributes to the development of BLM-induced fibrosis, we collected bronchoalveolar lavage (BAL) fluid on days 2, 7, 14 and 21 and determined the total and differential cell counts and concentrations of two proinflammatory cytokines (keratinocyte chemoattractant [KC] and interleukin [IL]-6) and two fibrogenic mediators (CC chemokine ligand 2 [CCL2] and transforming growth factor-β 1 [TGF-β 1]). Expression of nitrotyrosine, an indicator of oxidant injury, was also evaluated on days 7 and 21. CBNP, when combined with BLM, significantly enhanced BLM-induced increase in lung collagen content, decrease in lung compliance, and fibrotic changes in histopathology. CBNP significantly augmented BLM-induced increase in the numbers of inflammatory cells in BAL fluid on days 2 and 7 and levels of KC and IL-6 on day 2. In addition, CBNP administered in combination with BLM significantly elevated the levels of CCL2 on days 2, 7 and 14, and TGF-β 1 on day 14 in BAL fluid as compared with BLM alone. Nitrotyrosine expression was also increased by BLM plus CBNP compared with BLM alone. In contrast, CBNP did not exert any significant effect on these parameters by itself. These results indicate that CBNP can exaggerate BLM-induced inflammatory and fibrotic changes in the lung, suggesting the potential impact of nanoparticles on lung inflammation and fibrosis.

AB - With the recent increasing use of nanoparticles, there is concern that they may become an environmental risk factor as airborne particles. However, the impact of these particles on susceptible subjects with predisposing lung disease have not been sufficiently elucidated. In the present study, we investigated the effects of nanoparticles on pulmonary inflammatory and fibrotic changes induced by intratracheal bleomycin (BLM) challenge in mice. Mice were intratracheally administered either vehicle, 14-nm carbon black nanoparticles (CBNPs), BLM or BLM plus CBNP. First, we assessed lung collagen content, lung compliance and fibrotic changes in histopathology on day 21 after instillation. Then, to elucidate how CBNP contributes to the development of BLM-induced fibrosis, we collected bronchoalveolar lavage (BAL) fluid on days 2, 7, 14 and 21 and determined the total and differential cell counts and concentrations of two proinflammatory cytokines (keratinocyte chemoattractant [KC] and interleukin [IL]-6) and two fibrogenic mediators (CC chemokine ligand 2 [CCL2] and transforming growth factor-β 1 [TGF-β 1]). Expression of nitrotyrosine, an indicator of oxidant injury, was also evaluated on days 7 and 21. CBNP, when combined with BLM, significantly enhanced BLM-induced increase in lung collagen content, decrease in lung compliance, and fibrotic changes in histopathology. CBNP significantly augmented BLM-induced increase in the numbers of inflammatory cells in BAL fluid on days 2 and 7 and levels of KC and IL-6 on day 2. In addition, CBNP administered in combination with BLM significantly elevated the levels of CCL2 on days 2, 7 and 14, and TGF-β 1 on day 14 in BAL fluid as compared with BLM alone. Nitrotyrosine expression was also increased by BLM plus CBNP compared with BLM alone. In contrast, CBNP did not exert any significant effect on these parameters by itself. These results indicate that CBNP can exaggerate BLM-induced inflammatory and fibrotic changes in the lung, suggesting the potential impact of nanoparticles on lung inflammation and fibrosis.

KW - Bleomycin

KW - Lung inflammation

KW - Nanoparticle

KW - Oxidant injury

KW - Pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=79953203624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953203624&partnerID=8YFLogxK

U2 - 10.1258/ebm.2011.010180

DO - 10.1258/ebm.2011.010180

M3 - Article

C2 - 21427237

AN - SCOPUS:79953203624

VL - 236

SP - 315

EP - 324

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 0037-9727

IS - 3

ER -